Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Gains from Investment Securities (2020 - 2024)

Historic Gains from Investment Securities for Keros Therapeutics (KROS) over the last 5 years, with Q3 2024 value amounting to $5.7 million.

  • Keros Therapeutics' Gains from Investment Securities changed N/A to $5.7 million in Q3 2024 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $5.7 million for FY2024, which is 32877.43% up from last year.
  • According to the latest figures from Q3 2024, Keros Therapeutics' Gains from Investment Securities is $5.7 million.
  • In the past 5 years, Keros Therapeutics' Gains from Investment Securities ranged from a high of $15.4 million in Q4 2022 and a low of -$755000.0 during Q4 2021
  • Its 5-year average for Gains from Investment Securities is $2.8 million, with a median of $386500.0 in 2020.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 161590.91% in 2021, then soared by 214423.84% in 2022.
  • Quarter analysis of 5 years shows Keros Therapeutics' Gains from Investment Securities stood at -$44000.0 in 2020, then plummeted by 1615.91% to -$755000.0 in 2021, then skyrocketed by 2144.24% to $15.4 million in 2022, then crashed by 91.33% to $1.3 million in 2023, then surged by 328.77% to $5.7 million in 2024.
  • Its last three reported values are $5.7 million in Q3 2024, $1.3 million for Q1 2023, and $15.4 million during Q4 2022.